clopidogrel [Design Issues]

posted by Ohlbe – France, 2007-03-30 19:44 (7023 d 17:50 ago) – Posting: # 607
Views: 10,686

Dear Velupharm,

The situations where metabolites can be used instead of the parent compound are listed in the EU Note for guidance on bioequivalence and commented upon in the Q&A document issued by EMEA last year (see here).

In a presentation at the DIA Euromeeting on Wednesday this week Martin Olling from the Dutch Medicines Evaluation Board really insisted on the use of the parent compound whenever possible.

Exclusive use of a metabolite, especially a non-active metabolite, could lead to real problems and should be appropriately justified. I am not sure reference to the LOQ mentioned in the SmPC, deriving from a bioanalytical method developped 10 years ago or more, would be considered as a sufficient justification ;-).

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
207 visitors (0 registered, 207 guests [including 96 identified bots]).
Forum time: 13:34 CEST (Europe/Vienna)

Scientists cannot simply hang their subjectivities
up on a hook outside the laboratory door.    Ruth Bleier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5